Dergiler / Haseki Tıp Bülteni / 2018 / Cilt: 56 - Sayı: 2

The Prevalence of Paroxysmal Nocturnal Hemoglobinuria Clone in Adult Patients with Idiopathic Pulmonary Hypertension

İdiyopatik Pulmoner Hipertansiyonu Olan Erişkin Hastalarda Paroksismal Noktürnal Hemoglobinüri Klonu Prevelansı

Sayfa
114–117
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Screening for PNH clone in patients with pHT, who have normal LDH levels is unnecessary.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: Paroxysmal nocturnal hemoglobinuria (PNH) a is a clonal disorder that may lead to several conditions such as thromboses, Budd-Chiari syndrome, renal failure, impotence, and pulmonary hypertension (pHT).
📊
Temel Bulgular & Veri:Methods: A total of 45 patients with pHT were screened for PNH clone by proaerolysin conjugated with fluorescein.
💡
Sonuç & Katkı:Conclusion: Screening for PNH clone in patients with pHT, who have normal LDH levels is unnecessary.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Aim: Paroxysmal nocturnal hemoglobinuria (PNH) a is a clonal disorder that may lead to several conditions such as thromboses, Budd-Chiari syndrome, renal failure, impotence, and pulmonary hypertension (pHT). Since the presentation of PNH may be occult, monitoring for clonal evolution is recommended in certain situations including aplastic anemia, Myelodysplastic syndrome, and unexplained cytopenia, and thrombosis. The prevalence of PNH clone in patients with idiopathic pHT is unknown. We designed a study to determine the prevalence of PNH clone in patients with idiopathic pHT, since it may be the first isolated presentation of the disease. Methods: A total of 45 patients with pHT were screened for PNH clone by proaerolysin conjugated with fluorescein. Results: Only two out of 45 patients had elevated lactate dehydrogenase (LDH) levels at presentation. PNH clone was detected in none of the patients. Conclusion: Screening for PNH clone in patients with pHT, who have normal LDH levels is unnecessary.

Abstract

Amaç: Paroksismal noktürnal hemoglobinüri (PNH) tromboz, Budd-Chiari sendromu, böbrek yetmezliği, impotans, pulmoner hipertansiyon (pHT) gibi çeşitli hastalıklara sebebiyet verebilen klonal bir hastalıktır. PNH’nin prezentasyonu sessiz olabileceğinden, aplastik anemi, Miyelodisplastik sendrom, açıklanamaya sitopeniler ve tromboz gibi çeşitli durumlarda PNH klonu taranması önerilmektedir. İdiyopatik pHT’si olan hastalarda PNH klonu prevalansı ise bilinmemektedir. PNH’li hastalarda pHT hastalığın ilk bulgusu olabileceğinden, pulmoner hipertansiyonu olan hastalarda PNH klonu prevelansını belirlemek amacıyla bir çalışma tasarladık. Yöntemler: pHT’si olan toplam 45 hastada florasanla konjuge proaerolizin yöntemiyle PNH klonu tarandı. Bulgular: Kırk beş hastanın yalnızca ikisinde başlangıç laktat dehidrogenaz (LDH) düzeyi normalin üzerindeydi. PNH klonu hiçbir hastada saptanmadı. Sonuç: LDH düzeyi normal olan pHT hastalarında PNH klonu taranması gerekli görülmemiştir.

🔖

Bu Makaleye Atıf Yap

AYER, M., ELİBOL, T., SİNAN, Ü. Y., BAL, C., KÜÇÜKOĞLU, M. S. (2018). The Prevalence of Paroxysmal Nocturnal Hemoglobinuria Clone in Adult Patients with Idiopathic Pulmonary Hypertension. Haseki Tıp Bülteni, Cilt: 56 - Sayı: 2, 114–117. https://ajindex.com/articles/198178

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67-119. Charles J. Parker. ASH Education Book December 10. Hematology 2011;1:21-9.
  2. Hill A, Rother RP, Wang X, et al. Effect of eculizumab on haemolysisassociated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2010;149:414-25.
  3. Rother RP, Bell L, Hillmen P, Gladwin MT. The Clinical sequele of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 2005;293:1653- 62. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30.
  4. Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012;186:790-6. Hernández-Campo PM, Almeida J, Acevedo MJ, et al. Detailed immunophenotypic characterization of different major and minor subsets of peripheral blood cells in patients with paroxysmal nocturnal hemoglobinuria. Transfusion 2008;48:1403-14.
  5. Richards SJ, Whitby L, Cullen MJ, et al. Development and evaluation of a stabilized whole-blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry. Cytometry B Clin Cytom 2009;76:47-55.
  6. Borowitz MJ, Craig FE, Digiuseppe JA, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 2010;78:211-30.
  7. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk Factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-95.
  8. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005;293:1653- 62. Schnog JJ, Jager EH, van der Dijs FP, et al. Evidence for a metabolic shif